Results from the phase III study (NCT02252042) assessing the antitumor activity and toxicity of pembrolizumab in patients with recurrent or metastatic HNSCC showed a lower risk of death in patients with high tumor PD-L1 expression, and this despite missing predetermined endpoints. This evidence concerns the gene CD274 and neoplasm.